InvestorsHub Logo
Followers 53
Posts 1783
Boards Moderated 0
Alias Born 03/22/2015

Re: dr_lowenstein post# 163006

Monday, 08/24/2015 8:46:30 AM

Monday, August 24, 2015 8:46:30 AM

Post# of 403182

I agree that elite MAY gain market share in the acute pain market IF their tech is any good at all, however, I do not see the ultimate leap into the chronic pain market.




Doc, another easy addition to the immediate-release stable would be hydrocodone. This would require Phase 3 because there is no currently available hydrocodone without acetaminophen, but it should be no more complicated than ELI-200's 162-patient bunion beater. Internists tend to be purists- I prescribe mostly oxyIR, rarely Percocet (Tylenol added). Rarely Norco/Lortab nee Vicodin. I would use straight hydrocodone IR if it was available, but it's not. Probably some formulation issue- who knows? But it seems right in the strike-zone of Elite with patented microtablet technology. It would be a brand new thing, and as such, it would get a lot of attention, especially with its advanced ADF tech. I'd give it to Epic and let them build an acute pain specialty division.

I liked Money Tree's number for immediate-release opioids: $5.9 billion. And quick & dirty you're sitting on that market with Official FDA ADF-labeled oxycodone and hydrocodone.

Immediate-release, indeed.

"There are three kinds of lies: lies, damned lies, and statistics."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News